血清学指标对肝硬化程度的预测分析  

The predictive analysis of the degree of live cirrhosis by serological indication

作　　者：徐巧叶 崔维军 朱怀青 

机构地区：[1]上虞市第二人民医院检验科,浙江省上虞312365

出　　处：《中国基层医药》2013年第20期3085-3087,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨不同程度肝硬化患者临床血清学指标，评价和判断在诊断中的应用价值。方法肝硬化代偿期和失代偿期患者各50例，对照组50例，对其相关血清学指标进行统计分析。结果失代偿期肝硬化总胆红素（TBIL）和丙氨酸氨基转移酶（ALT）分别为（69．5±7．0）μmol／L、（143．1±14．2）U／L，高于代偿期肝硬化[（44．6±5．8）Ixmol／L、（77．4±8．6）U／L，P〈0．05]；两组均高于对照组（P〈0．05）；失代偿期肝硬化血清白蛋白（Alb）和胆碱酯酶（ChE）分别为（28．2±3．7）e,／L和（2024．39±211．40）U／L，均低于对照组（36．1±3．7）g／L、（6169．36±607．42）U／L和代偿期肝硬化[（34．7±4．3）g／L（3571．27±310．01）U／L]（P〈0．05）；代偿期肝硬化组ChE低于对照组（P〈0．05）。失代偿期肝硬化和代偿期肝硬化前白蛋白（PA）和腺苷脱氨酶（ADA）分别为（0．14±0．04）mg／I。、（16．17±1．94）U／L和（0．21±0．05）mg,／L、（34．20±3．29）U／L，差异有统计学意义（P〈0．05）。失代偿期肝硬化和代偿期肝硬化A／G分别为（0．64±0．29）和（I．06±0．30），均低于对照组（1．51±0．21）（P〈0．05），且失代偿期肝硬化低于代偿期肝硬化（P〈0．05）。失代偿期肝硬化Ⅳ型胶原（Ⅳ-c）和层黏连蛋白（LN）分别为（97．4±9．8）肛g／L和（205．7±20．1）斗g／I。，均高于代偿期肝硬化（68．7±7．5）斗g／L和（124．1±11．8）肛g／L和对照组[（52．3±6．1）U/L和（83．8±7．6）U/L]，且代偿期肝硬化组高于对照组（P〈0．05）；失代偿期肝硬化透明质酸（HA）、HI型前胶原（PCⅢ）分别为（211．3±16．4）肛g,／L和（168．1±16．2）U/L，均高于对照组（51．2±5．3）Ixg／L和（79．1±8．0）斗∥L（P〈0．05）。结论丙氨酸氨基转移酶等几项血清学指标对于不同肝硬化程度临床�Objective To explore the clinical value of serological indicators in diagnosis of patients with different degree of liver cirrhosis. Methods 50 patients with liver cirrhosis and 50 patients with decompensate cirrhosis were selected. The control group had 50 patients. The serological indicators were statistically analyzed. Results TBIL and ALT in the decompensated liver cirrhosis group were （69.5± 7.0）μmol/L, （143.1 ± 14.2 ）U/L, which were higher than those of compensated liver cirrhosis group （ 44.6 ± 5.8 ） μmol/L, （ 77.4 ± 8.6 ） U/L （ P 〈 0.05 ）, and those two groups were higher than the control group（P 〈 0.05）. Alb and ChE of decompensated liver cirrhosis group were （28.2 ± 3.7 ）g/L and （2024.39 ± 211.40）U/L, which were lower than those of the control group （36. 1 ± 3.7 ） g/L, （6169.36 ± 607.42 ） U/L and the compensated cirrhosis group [ （ 34.7 ± 4.3 ） g/L, （ 3571.27 ± 310.01 ） U/L] （ P 〈 0.05）. ChE of compensated cirrhosis group was lower than the control group （ P 〈 0.05 ）. PA and ADA of decompensated and compensated liver cirrhosis group were （0.14 ± 0.04）rag/L, （16.17 ± 1.94）U/L and （0. 21 ± 0.05 ） mg/L, （ 34.20 ± 3.29 ） U/L, the differences were statistically significant （ P 〈 0.05 ）. A/G of decompensated and compensated liver cirrhosis group were （0.64 ± 0.29） and （ 1.06 ± 0.30）, which were lower than the control group （ 1.51 ± O. 21 ） （ P 〈 0.05 ）, and that of the decompensated cirrhosis group was lower than that of the compensa- ted cirrhosis group （P 〈 0.05）. IV-C and LN of decompensated cirrhosis group were （97.4 ± 9.8） p±g/L and （205.7 ± 20.1 ） ixg/L,which were higher than those of compensated liver cirrhosis group （68.7 ± 7.5 ） p.g/L and （ 124.1 ± 11.8 ）μg/L and the control group （52.3 ± 6.1 ）μg/L and （83.8 ± 7.6）μg/L（ P 〈 0.05 ）. And those of the compensated cirrhosis group were higher than the control group （ P 〈 0.05 ）. HA a

关 键 词：肝硬化 肝功能研究 血清 丙氨酸氨基转移酶 透明质酸葡糖胺酶 层黏连蛋白 

分 类 号：R575.2[医药卫生—消化系统]